Trittico CR 150 mg: A Higher-Dose Sustained-Release Antidepressant for Severe Depression with Anxiety and Insomnia

When a depressive disorder reaches substantial depth, and both the anxiety and dyssomnia components dominate the clinical presentation, clinicians frequently escalate trazodone beyond the starting dose. Trittico CR 150 mg is a controlled-release tablet, each containing 150 mg of trazodone hydrochloride (equivalent to 136.6 mg of trazodone base). This dosage halves the pill burden compared to the 75 mg form, improving patient compliance while delivering a robust, round-the-clock therapeutic coverage. The drug retains the full spectrum of trazodone’s properties: a combined antidepressant, anxiolytic, and sleep-normalizing action.

🔬 Pharmacodynamic Rationale: A Multi-Receptor Strategy for Depression

Trazodone occupies a distinct place in antidepressant classification. It belongs neither to the SSRIs, nor the tricyclics, nor the MAOIs — it carves out its own niche, designated as a Serotonin Antagonist and Reuptake Inhibitor (SARI). The key mechanistic nodes are:

1. Serotonin Transporter (SERT) Inhibition. By elevating synaptic serotonin concentrations, the drug initiates long-term adaptive alterations in the neuronal receptor apparatus, which underpins the antidepressant response.
2. Blockade of 5-HT₂A and 5-HT₂C Receptors. This is the fundamental point of distinction from SSRIs. By disinhibiting these receptor subtypes, SSRIs frequently provoke akathisia, anxiety, and sexual dysfunction. Trazodone, conversely, silences them, yielding the following:
   • The anxiolytic effect is clinically meaningful from the very first days of treatment.
   • Sexual function is not compromised; in some cases, it may improve as depressive symptoms recede.
   • Sleep architecture is restored in a physiological manner: the proportion of slow-wave sleep expands, and nocturnal awakenings are curtailed.
3. Moderate α₁-Adrenoceptor Antagonism. Supplies the sedative component, beneficial for patients with pronounced agitation and insomnia, but concurrently demands caution in individuals prone to hypotension.

📋 When Escalation to 150 mg is Justified

Trittico CR 150 mg is prescribed in the following clinical scenarios:

• Severe depressive episodes requiring dose escalation after a titration period initiated with 75 mg.
• Depressions with dominating anxious symptomatology, where the standard dose fails to adequately contain generalized anxiety and panic attacks.
• Protracted depressive states with resistance to initial therapy, where within-molecule dose escalation is preferable to premature polypharmacy.
• Prominent dyssomnia within the depressive structure, demanding a reliable somnogenic effect without the addition of benzodiazepines or Z-hypnotics.
• Maintenance therapy in patients stabilized on 150 mg/day, where a single evening intake achieves full therapeutic coverage.

💊 CR Formulation Features and Administration Rules

• Controlled-Release System. The tablet matrix is engineered to deliver the active substance into the bloodstream gradually, avoiding sharp plasma concentration spikes. This is critical for minimizing dose-dependent adverse effects such as sedation and dizziness.
• Tablet Integrity. Trittico CR must never be broken, chewed, or crushed. Any breach of the tablet’s structure destroys the prolonged-release matrix, effectively converting the dose into an immediate-release bolus with an unpredictable pharmacokinetic profile and an elevated side-effect risk.
• Dosing Schedule: One tablet once daily, in the evening or directly at bedtime, on an empty stomach. Taking the dose on an empty stomach reduces the likelihood of gastrointestinal reactions.
• Titration: Transition to the 150 mg dose must proceed under medical supervision, typically following 3–7 days of therapy at 75 mg. Independent dose doubling is inadmissible.

⚠️ Contraindications and Precautionary Measures

Trittico CR 150 mg is absolutely contraindicated in the setting of:

• Individual hypersensitivity to trazodone or any excipient.
• Acute myocardial infarction.
• Acute intoxication with alcohol or hypnotic agents.

Mandatory Disclosure to the Physician Before Commencing Therapy:

• Hepatic and/or Renal Insufficiency. Trazodone metabolism occurs in the liver, while metabolite elimination depends on renal function. In cases of significant organ dysfunction, dose adjustment may be required.
• Cardiac Pathology. Especially bradycardia, coronary artery disease, and congenital or acquired QT interval prolongation. Trazodone possesses the capacity to lengthen the QT interval, which, in combination with other proarrhythmogenic factors, can trigger torsades de pointes ventricular tachycardia.
• Psychotic Disorders. In patients with schizophrenia or bipolar disorder, trazodone may intensify psychotic symptoms or precipitate a manic switch.
• Epilepsy. The drug can lower the seizure threshold.
• Hyperthyroidism.
• Urinary Outflow Obstruction (e.g., prostatic adenoma).
• Narrow-Angle Glaucoma.
• Predisposition to Bleeding (including iatrogenic — while taking anticoagulants or antiplatelet agents).
• Pregnancy, Lactation, and Pediatric Use Under 18 — use is permissible only in exceptional circumstances at the physician’s discretion.

📊 Adverse Reactions

The side-effect spectrum of trazodone is broad; however, most are dose-dependent and may regress with adequate titration and schedule adherence:

• Most Frequent: Somnolence, dizziness, dry mouth, nausea.
• Cardiovascular: Orthostatic hypotension (especially in the elderly), QT prolongation, arrhythmias including torsades de pointes.
• Psychiatric and Neurological: Suicidal ideation at treatment initiation, confusion, agitation, mania, hallucinations, serotonin syndrome, seizures, tremor, myoclonus.
• Hematological: Agranulocytosis, thrombocytopenia, leukopenia, anemia.
• Hepatobiliary: Jaundice, hepatocellular injury, intrahepatic cholestasis.
• Urological: Urinary retention, incontinence.
• Reproductive System: Priapism — an absolute indication for emergency medical intervention.

🛡️ Critical Cautions

Suicide Risk. The initial weeks of antidepressant therapy are associated with a paradoxical increase in the risk of suicidal thoughts and acts. This arises because psychomotor retardation tends to lift more rapidly than the affective symptoms. The patient’s relatives must be alerted to this window, and the patient must be instructed to seek immediate help should suicidal impulses emerge.

Withdrawal Syndrome. Abrupt cessation of Trittico CR, particularly at the 150 mg dose, can provoke nausea, headache, irritability, and insomnia. Discontinuation must proceed gradually, under medical supervision.

False-Positive Drug Screens. Immunochemical urine drug tests may yield false-positive results for amphetamines (MDMA/ecstasy) due to cross-reactivity with trazodone metabolites. In the event of a disputed result, confirmatory analysis using chromatographic-mass spectrometric methods is mandatory.

Driving and Machinery Operation. The somnolence and sedation characteristic of trazodone render driving and operation of potentially hazardous equipment contraindicated during the dose-finding phase and until the individual reaction profile has been clarified.

📦 Storage

Store in the original packaging, out of children’s reach, at room temperature.

📦Find out about the delivery to your country on WhatsApp